Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors

Lemborexant, a recently approved dual orexin receptor antagonist for treatment of adults with insomnia, is eliminated primarily by cytochrome P450 (CYP)3A metabolism. The recommended dose of lemborexant is 5 mg once per night, with a maximum recommended dose of 10 mg once daily. A physiologically‐ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueno, Takashi, Miyajima, Yukiko, Landry, Ishani, Lalovic, Bojan, Schuck, Edgar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129715/
https://www.ncbi.nlm.nih.gov/pubmed/33704920
http://dx.doi.org/10.1002/psp4.12606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129715/
https://www.ncbi.nlm.nih.gov/pubmed/33704920
http://dx.doi.org/10.1002/psp4.12606

Ejemplares similares